Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Advisory Committee Features Actual Debate About Biosimilarity

Jul 14 2016

• By Derrick Gingery

formula

Related Content

Biosimilars Education Needs To Come From Industry, Not FDA, NACDS Says

Feb 24 2016

US FDA's inaugural biosimilar review bumpier than first appeared

Jun 15 2015

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Jul 13 2016

Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis

Jul 11 2016

Biosimilar Advisory Committees Will Focus Less On Clinical Data

Jan 25 2016

Pending Biosimilars

Mar 07 2016

Related Companies

Novartis AG

Amgen, Inc.

Amgen, Inc.

AbbVie Inc.

Additional Topics

United States Advisory Committees Review Pathway Drug Review Regulation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window